(CALGB 90203) A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer -
Description: 

The purpose of this study is to determine whether treatment with chemotherapy and hormonal therapy prior to prostate surgery will increase progression free survival compared to treatment with immediate prostate surgery alone for high risk prostate cancer patients (patients with a predicted chance of cure with surgery at 15 years follow-up of less than 60%). Patients will be randomized into one of two groups. Group 1 will be treated with chemotherapy and hormone therapy for approximately 4 monthsprior to surgery. In group 2, patients will be treated immediately with surgery alone.

Study Number: 

NCG 100607

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT00430183

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.